Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s share price was up 1.3% during mid-day trading on Monday . The stock traded as high as $47.88 and last traded at $47.80. Approximately 3,700,512 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 4,927,286 shares. The stock had previously closed at $47.17.
Analysts Set New Price Targets
Several equities analysts recently issued reports on TEM shares. Morgan Stanley raised their price target on Tempus AI from $50.00 to $60.00 and gave the company an "overweight" rating in a report on Thursday, March 6th. Piper Sandler decreased their price target on Tempus AI from $70.00 to $55.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. TD Cowen reiterated a "buy" rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Needham & Company LLC raised their price target on Tempus AI from $56.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Finally, JPMorgan Chase & Co. cut Tempus AI from an "overweight" rating to a "neutral" rating and raised their price target for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.18.
Check Out Our Latest Stock Analysis on Tempus AI
Tempus AI Trading Up 0.0 %
The firm has a 50 day simple moving average of $56.07 and a two-hundred day simple moving average of $51.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.
Insider Transactions at Tempus AI
In other news, Director David R. Epstein sold 990 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $46.83, for a total transaction of $46,361.70. Following the sale, the director now owns 26,284 shares of the company's stock, valued at $1,230,879.72. This trade represents a 3.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the sale, the chief accounting officer now directly owns 57,237 shares in the company, valued at approximately $3,434,220. This represents a 19.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,598,969 shares of company stock valued at $317,194,162 over the last 90 days.
Institutional Investors Weigh In On Tempus AI
Hedge funds and other institutional investors have recently bought and sold shares of the company. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the 3rd quarter valued at approximately $30,000. Operose Advisors LLC bought a new stake in shares of Tempus AI during the 4th quarter worth approximately $25,000. Farther Finance Advisors LLC bought a new stake in Tempus AI in the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC raised its stake in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after acquiring an additional 965 shares during the period. Finally, NewEdge Advisors LLC bought a new stake in Tempus AI in the 4th quarter valued at $49,000. Institutional investors and hedge funds own 24.22% of the company's stock.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Stories
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
